A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer. - Trial NCT06321510
Access comprehensive clinical trial information for NCT06321510 through Pure Global AI's free database. This phase not specified trial is sponsored by Pfizer and is currently Not yet recruiting. The study focuses on Lung Cancer. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Pfizer
Timeline & Enrollment
N/A
Apr 01, 2024
Mar 15, 2025
Primary Outcome
Percentage of patients with dacomitinib dosage change and reasons,Percentage of patients with dacomitinib treatment discontinuation
Summary
The purpose of this study is to learn about dacomitinib for the possible treatment of lung
 cancer.
 
 This study is seeking participants who:
 
 - have lung cancer that could not be controlled.
 
 - have a type of gene called epidermoid growth factor receptor. A gene is a part of your
 DNA that has instructions for making things your body needs to work.
 
 - have received dacomitinib for their lung cancer.
 
 All participants in this study had received dacomitinib. Dacomitinib is a tablet that is
 taken by mouth at home. They continued to take dacomitnib until their cancer was no longer
 responding. The study will look at the experiences of people receiving the study medicine.
 This will help to see if the study medicine is safe and effective.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06321510
Non-Device Trial